Priligy (Dapoxetine), a drug developed for the treatment of premature ejaculation, may have a protective effect against benign prostatic hyperplasia induced by testosterone (BPH), according to a study of rats by Egyptian scientists.
The study, “Dapoxetine attenuates testosterone induced prostatic hyperplasia in rats by regulating inflammatory and apoptotic proteins,” was published in the journal Toxicology and Applied Pharmacology.
Researchers led by Dr. Ayman El-Sahar, with the Department of Pharmacology and Toxicology at the University of Cairo, first analyzed the effect of dapoxetine on prostate weight in rats with BPH, induced by the injection of a Daily dose of testosterone under the skin.
The rats were then divided into four groups. The animals in the first group did not receive any other treatment, whereas those in the other three groups received 1 mg / kg, 5 mg / kg and 10 mg / kg dapoxetine, respectively. The animals were then sacrificed and the weight of their prostates measured.
The results showed that there was a clear relationship between the dose of dapoxetine and the weight of the prostate of the animals, with the weight of the prostate decreasing with increasing dose levels of dapoxetine. However, there was no difference in prostate weight of rats treated with 5 mg / kg or 10 mg / kg of dapoxetine. Interestingly, the doses of 10 mg / kg and 1 mg / kg dapoxetine had the same effect on the relative weight of the prostate, which is the weight of the prostate over total body weight. Therefore, 5 mg / kg dapoxetine was determined as the optimal dose to be used for further experiments.
The researchers then performed a mechanistic analysis where the rats were again divided into four groups. The animals in the first group received no treatment and constituted the control group. BPH was induced in the animals in the three remaining groups, again using daily injections of testosterone. The animals in the second group did not receive any other treatment, those in the third group received 5 mg / kg of dapoxetine, and those in the fourth group received 5 mg / kg of finasteride, which is often used to treat BPH. The animals’ prostates were again removed and weighed.
Here, the results showed that the testosterone injection caused the prostate weight to increase by about 250%. Although none of the drugs could return the prostate to its weight before the testosterone injection, finasteride reduced prostate relative weight by 44% and dapoxetine by 45% in testosterone-treated rats. These findings suggest that dapoxetine may be as effective as finasteride in reducing prostate weight in rats induced by testosterone.
“However, more clinical research on this topic should be conducted prior to the association between dapoxetine and the prevention of prostatic hyperplasia being more clearly understood and practically used,” the authors wrote.
The researchers also observed that both finasteride and dapoxetine reversed most of the changes in the body of the rats by injecting testosterone, such as the expression of the androgen receptor and pathological changes in the prostate tissue. Researchers suggested that dapoxetine could improve testosterone-induced prostatic growth by inhibiting cell proliferation and inflammation and by inducing programmed cell death.
Priligy (Dapoxetine) is not a treatment approved by the Food and Drug Administration for any indication, and the FDA states in a statement that its safety or efficacy has not been determined.